title: Injectable contraception: updates and innovation.
abstract: Injectable contraception is a highly effective form of birth control that is globally popular. Recent research has focused on ways to make injectables such as depot medroxyprogesterone acetate (DMPA) more accessible and to improve the side-effect profile of injectables. This review will focus on new directions and approaches to the use of injectable contraception.
  
  
  
  Research in the area of injectable contraception has focused on improving access for women through home or self-injection, and also task-shifting and community-based distribution in low-resource areas. Specific to DMPA, studies have focused on lowering the overall dose of medication while maintaining efficacy, and improving drug-delivery systems. More research into the association between DMPA and HIV is needed, and also the effects of administration of DMPA at the time of medication abortion.
  
  
  
  Injectable contraceptives are an important part of the global method mix of highly effective birth control. Improving the accessibility and side effect profile of commodities such as DMPA will make injectables even more valuable for women seeking effective contraception.
authors: aStanford University School of Medicine, Stanford, California bFHI 360, Durham, North Carolina, USA.
authors: Gillian
authors: G
authors: Schivone
authors: Laneta
authors: L
authors: Dorflinger
authors: Vera
authors: V
authors: Halpern
mesh_terms: D000028:Abortion, Induced; D000328:Adult; D003267:Contraception / Q000379:methods* / Q000639:trends; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D005193:Family Planning Services / Q000379:methods* / Q000639:trends; D005260:Female; D015658:HIV Infections / Q000150:complications; D006297:Health Services Accessibility; D006801:Humans; D007267:Injections; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D009640:Norethindrone / Q000008:administration & dosage*; D010349:Patient Compliance; D011247:Pregnancy; D049168:Pregnancy, Unplanned; D012306:Risk
chemical_list: D003271:Contraceptive Agents, Female; D017258:Medroxyprogesterone Acetate; D009640:Norethindrone